What is Inotiv Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Inotiv's interest expense for the
three
months ended in Dec. 2023 was $ -11.4 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-43.9 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Inotiv's Operating Income for the
three
months ended in Dec. 2023 was $ -8.3 Mil. Inotiv's Interest Expense for the
three
months ended in Dec. 2023 was $ -11.4 Mil.
Inotiv did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Inotiv Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inotiv (NAS:NOTV) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Inotiv's Interest Expense for the
three
months ended in Dec. 2023 was $-11.4 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-8.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $409.0 Mil.
Inotiv's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Inotiv did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Inotiv (Inotiv) Business Description
Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
| John Gregory Beattie |
officer: Chief Operating Officer |
C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906 |
| Michael Garrett |
officer: Chief Commercial Officer |
250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663 |
| Andrea Castetter |
officer: SVP, Gen. Counsel & Secretary |
2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382 |
| Mary Theresa Coelho |
director |
52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
| John E Sagartz |
director, officer: Chief Strategy Officer |
19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043 |
| David Landman |
director |
2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382 |
| Robert Jr. Leasure |
director, officer: President and CEO |
C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382 |
| Beth Taylor |
officer: Chief Financial Officer |
3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
| Jeffrey Arthur Krupp |
officer: Chief Human Resources Officer |
2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382 |
| William D Pitchford |
officer: Chief Human Resources Officer |
1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905 |
| R Matthew Neff |
director |
535 N. COLLEGE DRIVE, CARMEL IN 46032 |
| Jeffrey Brennan Freeman |
officer: VP-Finance & Corp. Controller |
2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382 |
| Davis Gregory Cole |
director |
C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906 |
| Nigel Brown |
director |
250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663 |
| Scott Cragg |
director |
660 MADISON AVENUE, NEW YORK NY 10065 |
Inotiv (Inotiv) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOTV has been successfully added to your 